ACOG
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Alpha Cognition announces publication of a U.S. patent application covering the proprietary manufacturing process for ZUNVEYLOct 13, 2026
- Alpha Cognition receives European patent for ZUNVEYL to treat mild-to-moderate Alzheimer's diseaseJul 29, 2026
- Alpha Cognition enrolled the first patient in the Phase 4 RESOLVE study of ZUNVEYL for mild-to-moderate Alzheimer's diseaseJun 16, 2026
- Alpha Cognition received a U.S. patent for ALPHA-1062 for traumatic brain injuryApr 2, 2026
- Alpha Cognition announced it will present new clinical data on ZUNVEYL (benzgalantamine) at upcoming Alzheimer's Association international conferencesMar 10, 2026